The Effect of Oral and Nasal Feeding on Cerebral Small Vessel Disease

Launched by ZENG CHANGHAO · Jan 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different feeding methods for patients with Cerebral Small Vessel Disease (CSVD) who have difficulty swallowing, a condition known as dysphagia. The trial compares the traditional method of feeding through a nasogastric (NG) tube, which is inserted through the nose into the stomach, with a newer method called Intermittent Oro-esophageal Tube Feeding (IOE), where a tube is placed in the mouth and down the throat. The goal is to see which method helps improve swallowing, nutritional health, daily activities, quality of life, and reduces the risk of pneumonia and other complications.

To be eligible for this trial, participants need to be between 40 and 70 years old, diagnosed with CSVD, and have difficulty swallowing as confirmed by specific tests. They should also be able to understand and cooperate during the study. However, those with swallowing problems from other causes or serious health issues, like severe liver or kidney failure, cannot participate. If you join the study, you can expect to receive care and support while helping researchers learn which feeding method is better for patients like you. This could contribute to improved treatment approaches for those with similar conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Cerebral Small Vessel Disease;
• • Must be able to cooperate with treatment and questionnaire investigation, (Generally with a Mini-Mental State Examination (MMSE) score ≥ 24) ;
• • Clinical diagnosis of dysphagia through the Functional Oral Intake Scale (FOIS) and Video Fluoroscopic Swallowing Study (VFSS);
• • Age between 40 and 70 years;
• • Enteral nutrition support was required and feasible.
• • No history of prior stroke.
• Exclusion Criteria:
• • Dysphagia related to other cerebrovascular diseases or caused by neurodegenerative diseases;
• • Complicated with severe liver and kidney failure, tumors, or hematological disorders;
• • Simultaneously need to undergo other therapy that might affect the outcomes of this study;
• • Pregnant or nursing females.